

Paolo Golino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4114893/publications.pdf>

Version: 2024-02-01

154
papers

5,808
citations

93792

39
h-index

97045

71
g-index

154
all docs

154
docs citations

154
times ranked

7157
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022, 18, 61-72.	1.0	8
2	Cardiovascular Involvement in Transthyretin Cardiac Amyloidosis. <i>Heart Failure Clinics</i> , 2022, 18, 73-87.	1.0	12
3	Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 739-749.	1.0	5
4	Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 27.	0.8	14
5	The Impact of the COVID-19 Outbreak on Patients' Adherence to PCSK9 Inhibitors Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 475.	1.0	9
6	Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octogenarians with atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 879-886.	0.8	9
7	The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?. <i>European Respiratory Journal</i> , 2022, 60, 2102276.	3.1	8
8	Cardioinhibitory syncope with asystole during nitroglycerin potentiated head up tilt test: prevalence and clinical predictors. <i>Clinical Autonomic Research</i> , 2022, 32, 167-173.	1.4	7
9	Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells. <i>Vascular Pharmacology</i> , 2021, 137, 106822.	1.0	10
10	Transcatheter Aortic Valve Implantation: The New Challenges of Cardiac Rehabilitation. <i>Journal of Clinical Medicine</i> , 2021, 10, 810.	1.0	6
11	Nursing Teleconsultation for the Outpatient Management of Patients with Cardiovascular Disease during COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2087.	1.2	19
12	Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review. <i>Neuromuscular Disorders</i> , 2021, 31, 281-290.	0.3	8
13	Percutaneous Left Atrial Appendage Occlusion: An Emerging Option in Patients with Atrial Fibrillation at High Risk of Bleeding. <i>Medicina (Lithuania)</i> , 2021, 57, 444.	0.8	7
14	Left Ventricular Deformation and Vortex Analysis in Heart Failure: From Ultrasound Technique to Current Clinical Application. <i>Diagnostics</i> , 2021, 11, 892.	1.3	6
15	Peripheral Artery Disease and Abdominal Aortic Aneurysm: The Forgotten Diseases in COVID-19 Pandemic. Results from an Observational Study on Real-World Management. <i>Medicina (Lithuania)</i> , 2021, 57, 672.	0.8	1
16	Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, e20-e29.	0.8	17
17	Fluid challenge and balloon occlusion testing in patients with atrial septal defects. <i>Heart</i> , 2021, , heartjnl-2021-319676.	1.2	2
18	Edoxaban (LIXIANA®) in the treatment of venous thromboembolism. <i>Future Cardiology</i> , 2021, 17, 779-791.	0.5	1

#	ARTICLE	IF	CITATIONS
19	Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 781335.	1.1	2
20	Left Ventricular dysfunction and lung congestion in athletes on anabolic androgenic steroids: a speckle tracking and stress lung echocardiography analysis. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
21	Global Left Ventricular Myocardial Work Efficiency in Heart Failure Patients with Cardiac Amyloidosis: Pathophysiological Implications and Role in Differential Diagnosis.. <i>Journal of Cardiovascular Echography</i> , 2021, 31, 157-164.	0.1	2
22	External validation of the increased wall thickness score for the diagnosis of cardiac amyloidosis. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
23	Oxidized low-density lipoproteins induce tissue factor expression in T-lymphocytes via activation of lectin-like oxidized low-density lipoprotein receptor-1. <i>Cardiovascular Research</i> , 2020, 116, 1125-1135.	1.8	15
24	Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. <i>American Journal of Cardiology</i> , 2020, 134, 83-90.	0.7	18
25	Vitamin D inhibits Tissue Factor and CAMs expression in oxidized low-density lipoproteins-treated human endothelial cells by modulating NF- κ B pathway.. <i>European Journal of Pharmacology</i> , 2020, 885, 173422.	1.7	17
26	Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 138-145.	0.8	41
27	The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3926.	1.0	12
28	Effect of Sacubitril-Valsartan in reducing depression in patients with advanced heart failure. <i>Journal of Affective Disorders</i> , 2020, 272, 132-137.	2.0	13
29	Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1621.	1.0	13
30	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 1944.	1.0	36
31	The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator. <i>Journal of Clinical Medicine</i> , 2020, 9, 1111.	1.0	26
32	Transcatheter closure of atrial septal defect in the elderly: Early outcomes and mid-term follow-up. <i>International Journal of Cardiology Congenital Heart Disease</i> , 2020, 1, 100058.	0.2	5
33	Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 970-976.	1.5	11
34	ST-elevation during head up tilt test: a challenging case in syncope unit. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	2
35	First Multi-Detector Computed Tomography Evidence of Transcatheter Pacing System Migration and Embolization into the Pulmonary Vasculature. <i>Korean Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 53, 310-312.	0.6	1
36	First Multi-Detector Computed Tomography Evidence of Transcatheter Pacing System Migration and Embolization into the Pulmonary Vasculature. <i>Korean Journal of Thoracic and Cardiovascular Surgery</i> , 2020, , .	0.6	0

#	ARTICLE	IF	CITATIONS
37	Safety and feasibility of balloon aortic valvuloplasty in non-TAVI centers: The BAV for life experience. Catheterization and Cardiovascular Interventions, 2019, 93, E63-E70.	0.7	12
38	Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants A Systematic Review. Seminars in Thrombosis and Hemostasis, 2019, 45, 205-214.	1.5	30
39	SERUM cardiac-specific biomarkers and atrial fibrillation in myotonic dystrophy type I. Journal of Cardiovascular Electrophysiology, 2019, 30, 2914-2919.	0.8	3
40	Radial pseudoaneurysm in elderly: a rare event with undefined therapeutical approach. A case report and literature review. Monaldi Archives for Chest Disease, 2019, 89, .	0.3	4
41	Cognitive Function and Atrial Fibrillation: From the Strength of Relationship to the Dark Side of Prevention. Is There a Contribution from Sinus Rhythm Restoration and Maintenance?. Medicina (Lithuania), 2019, 55, 587.	0.8	21
42	Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study. BioMed Research International, 2019, 2019, 1-6.	0.9	6
43	Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study. American Journal of Cardiovascular Drugs, 2019, 19, 421-427.	1.0	17
44	Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. Clinical Therapeutics, 2019, 41, 2549-2557.	1.1	40
45	Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late. Journal of Cardiovascular Pharmacology, 2019, 73, 207-214.	0.8	33
46	Update on Direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	0.8	10
47	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-6.	0.8	11
48	Patent foramen ovale with complex anatomy: Comparison of two different devices (Amplatzer Septal) Tj ETQq0 0 0 rgBT /Overlock 10 T 279, 47-50.	0.8	11
49	A systolic murmur late after infective endocarditis: Looking for the guilty. Journal of Cardiovascular Echography, 2019, 29, 183.	0.1	0
50	Splicing of platelet resident pre-mRNAs upon activation by physiological stimuli results in functionally relevant proteome modifications. Scientific Reports, 2018, 8, 498.	1.6	65
51	Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. Journal of Thrombosis and Thrombolysis, 2018, 45, 206-212.	1.0	22
52	Fluid challenge predicts clinical worsening in pulmonary arterial hypertension. International Journal of Cardiology, 2018, 261, 167-171.	0.8	18
53	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review. Seminars in Thrombosis and Hemostasis, 2018, 44, 370-376.	1.5	39
54	Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascular Pharmacology, 2018, 111, 62-70.	1.0	38

#	ARTICLE	IF	CITATIONS
55	Does cardiac pacing reduce syncopal recurrences in cardioinhibitory vasovagal syncope patients selected with head-up tilt test? Analysis of a 5-year follow-up database. <i>International Journal of Cardiology</i> , 2018, 270, 149-153.	0.8	17
56	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 22.	1.0	10
57	Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1086-1092.	1.1	62
58	Mitral prolapse: An old mysterious entity – The incremental role of multimodality imaging in sports eligibility. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 207.	0.1	7
59	Reference ranges and physiologic variations of left E/e' ratio in healthy adults: Clinical and echocardiographic correlates. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 101.	0.1	22
60	Usefulness of the external loop recorder in a patient with Myotonic Dystrophy type 1 and recurrent episodes of palpitations: evaluation of the follow-up from diagnosis to 6 month-post-cardiac interventional treatment. <i>Acta Myologica</i> , 2018, 37, 5-8.	1.5	0
61	Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy. <i>Acta Myologica</i> , 2018, 37, 227-231.	1.5	0
62	Heart transplantation in a patient with Myotonic Dystrophy type 1 and end-stage dilated cardiomyopathy: a short term follow-up. <i>Acta Myologica</i> , 2018, 37, 267-271.	1.5	5
63	Prognostic Factors in Patients With Stemi Undergoing Primary PCI in the Clopidogrel Era: Role of Dual Antiplatelet Therapy at Admission and the Smoking Paradox on Long-Term Outcome. <i>Journal of Interventional Cardiology</i> , 2017, 30, 5-15.	0.5	8
64	Left atrial appendage closure using AMPLATZER [®] devices: A large, multicenter, Italian registry. <i>International Journal of Cardiology</i> , 2017, 248, 103-107.	0.8	51
65	Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque. <i>Current Cardiology Reviews</i> , 2017, 13, 110-117.	0.6	31
66	Upregulation of TH/IL-17 Pathway-Related Genes in Human Coronary Endothelial Cells Stimulated with Serum of Patients with Acute Coronary Syndromes. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 1.	1.1	28
67	Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation. <i>Acta Myologica</i> , 2017, 36, 218-222.	1.5	3
68	Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo : A possible contribution of immunity to thrombosis?. <i>International Journal of Cardiology</i> , 2016, 218, 188-195.	0.8	24
69	Evolving Concepts in LDL-Lowering Strategies: Are We There?. <i>Journal of Clinical & Experimental Cardiology</i> , 2016, 7, .	0.0	2
70	Role of Tissue Factor in the Coagulation Network. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 708-717.	1.5	22
71	The adipokine apelin-13 induces expression of prothrombotic tissue factor. <i>Thrombosis and Haemostasis</i> , 2015, 113, 363-372.	1.8	18
72	Activating stimuli induce platelet microRNA modulation and proteome reorganisation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 96-108.	1.8	40

#	ARTICLE	IF	CITATIONS
73	Reactive oxygen species induce a procoagulant state in endothelial cells by inhibiting tissue factor pathway inhibitor. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 186-192.	1.0	19
74	Mickey Mouse in the cath lab. <i>International Journal of Cardiology</i> , 2015, 201, 378-379.	0.8	0
75	High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need. <i>Translational Medicine @ UniSa</i> , 2015, 12, 29-40.	0.8	4
76	Preoperative evaluation before MitraClip [®] : present and future perspective. <i>Future Cardiology</i> , 2014, 10, 725-744.	0.5	1
77	Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. <i>Current Atherosclerosis Reports</i> , 2014, 16, 435.	2.0	413
78	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. <i>European Heart Journal</i> , 2014, 35, 2213-2223.	1.0	78
79	Local cytokine production in patients with Acute Coronary Syndromes: A look into the eye of the perfect (cytokine) storm. <i>International Journal of Cardiology</i> , 2014, 176, 227-229.	0.8	13
80	Adipose tissue and vascular inflammation in coronary artery disease. <i>World Journal of Cardiology</i> , 2014, 6, 539.	0.5	42
81	Platelet Biology and Receptor Pathways. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 299-309.	1.1	64
82	C-reactive protein induces expression of matrix metalloproteinase-9: A possible link between inflammation and plaque rupture. <i>International Journal of Cardiology</i> , 2013, 168, 981-986.	0.8	46
83	Rapid ultrasound score as an indicator of atherosclerosis [™] clinical manifestations in a population of hypertensives. <i>Anatolian Journal of Cardiology</i> , 2013, 14, 9-15.	0.4	1
84	The effect of dual-chamber closed-loop stimulation on syncope recurrence in healthy patients with tilt-induced vasovagal cardioinhibitory syncope: a prospective, randomised, single-blind, crossover study. <i>Heart</i> , 2013, 99, 1609-1613.	1.2	52
85	Characteristics of new P2Y12 inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S22-S30.	0.6	4
86	Does a high percentage of right ventricular pacing influence the incidence of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients?. <i>Kardiologia Polska</i> , 2013, 71, 1147-1153.	0.3	21
87	The effect of atrial preference pacing on paroxysmal atrial fibrillation incidence in myotonic dystrophy type 1 patients: a prospective, randomized, single-blind cross-over study. <i>Europace</i> , 2012, 14, 486-489.	0.7	25
88	The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1533-1543.	0.6	14
89	The Main Determinant of Hypotension in Nitroglycerine Tilt-Induced Vasovagal Syncope. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 739-748.	0.5	20
90	Increased dispersion of ventricular repolarization in emery dreifuss muscular dystrophy patients. <i>Medical Science Monitor</i> , 2012, 18, CR643-CR647.	0.5	34

#	ARTICLE	IF	CITATIONS
91	C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2011, 152, 7-12.	0.8	39
92	Transcoronary Th-17 lymphocytes and acute coronary syndromes: new evidence from the crime scene?. <i>International Journal of Cardiology</i> , 2011, 153, 215-216.	0.8	11
93	Dispersion of repolarization and beta-thalassemia major: the prognostic role of QT and JT dispersion for identifying the high-risk patients for sudden death. <i>European Journal of Haematology</i> , 2011, 86, 324-331.	1.1	51
94	Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients. <i>International Journal of Hematology</i> , 2011, 93, 446-451.	0.7	31
95	Pathophysiological role of blood-borne tissue factor: should the old paradigm be revisited?. <i>Internal and Emergency Medicine</i> , 2011, 6, 29-34.	1.0	21
96	Platelets release matrix metalloproteinase-2 in the coronary circulation of patients with acute coronary syndromes: possible role in sustained platelet activation. <i>European Heart Journal</i> , 2011, 32, 316-325.	1.0	60
97	Tissue Factor Is Induced by Resistin in Human Coronary Artery Endothelial Cells by the NF- κ B-Dependent Pathway. <i>Journal of Vascular Research</i> , 2011, 48, 59-66.	0.6	58
98	The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor?. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 517-523.	0.6	44
99	Inflammation: The Link Between Obesity and Cardiovascular Risk. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 101-111.	0.8	1
100	Increased Heterogeneity of Ventricular Repolarization in Obese Nonhypertensive Children. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 1533-1539.	0.5	29
101	Does Bachmann's bundle pacing prevent atrial fibrillation in myotonic dystrophy type 1 patients? A 12 months follow-up study. <i>Europace</i> , 2010, 12, 1219-1223.	0.7	32
102	Nutcracker syndrome. <i>European Journal of Echocardiography</i> , 2009, 10, 993-993.	2.3	4
103	Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?. <i>Internal and Emergency Medicine</i> , 2009, 4, 25-34.	1.0	75
104	When chewing gum is more than just a bad habit. <i>Lancet, The</i> , 2009, 373, 1918.	6.3	4
105	Myocardial Strain Analysis in a Doxorubicin-Induced Cardiomyopathy Model. <i>Ultrasound in Medicine and Biology</i> , 2008, 34, 370-378.	0.7	32
106	The role of adiposity as a determinant of an inflammatory milieu. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 450-460.	0.6	33
107	Patients With Acute Coronary Syndrome Show Oligoclonal T-Cell Recruitment Within Unstable Plaque. <i>Circulation</i> , 2006, 113, 640-646.	1.6	116
108	C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. <i>Cardiovascular Research</i> , 2005, 68, 47-55.	1.8	126

#	ARTICLE	IF	CITATIONS
109	Free radicals and antioxidants in cardiovascular diseases. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 159-171.	0.6	37
110	Novel antithrombotic strategies in cardiovascular diseases. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 298-306.	2.3	2
111	Tissue Factor Binding of Activated Factor VII Triggers Smooth Muscle Cell Proliferation via Extracellular Signal-Regulated Kinase Activation. <i>Circulation</i> , 2004, 109, 2911-2916.	1.6	63
112	Oleuropein prevents oxidative myocardial injury induced by ischemia and reperfusion. <i>Journal of Nutritional Biochemistry</i> , 2004, 15, 461-466.	1.9	123
113	Inhibition of the Tissue Factor Coagulation Pathway. <i>Current Vascular Pharmacology</i> , 2004, 2, 319-327.	0.8	5
114	Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1438-1444.	1.2	493
115	Activated platelets stimulate tissue factor expression in smooth muscle cells. <i>Thrombosis Research</i> , 2003, 112, 51-57.	0.8	23
116	Massive chronic atrial thrombosis. <i>International Journal of Cardiology</i> , 2003, 90, 323-324.	0.8	1
117	Involvement of Tissue Factor Pathway Inhibitor in the Coronary Circulation of Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 108, 2864-2869.	1.6	41
118	Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1684-1689.	1.1	8
119	Targeting Tissue Factor as an Antithrombotic Strategy. <i>Seminars in Vascular Medicine</i> , 2003, 03, 205-214.	2.1	5
120	The inhibitors of the tissue factor:factor VII pathway. <i>Thrombosis Research</i> , 2002, 106, V257-V265.	0.8	49
121	Role of Tissue Factor Pathway Inhibitor in the Regulation of Tissue Factor-Dependent Blood Coagulation. <i>Cardiovascular Drug Reviews</i> , 2002, 20, 67-80.	4.4	22
122	Animal models of platelet-dependent thrombosis. , 2002, , 499-512.		0
123	How to study the effects of platelet aggregation and thrombosis on coronary vasomotion and their clinical relevance. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2002, 3, 220-5.	0.1	2
124	Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. <i>Journal of the American College of Cardiology</i> , 2001, 38, 569-576.	1.2	37
125	Direct coronary stenting: Effect on coronary blood flow, immediate and late clinical results. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 464-473.	0.7	66
126	Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 278, H1507-H1516.	1.5	49

#	ARTICLE	IF	CITATIONS
127	Endogenous Tissue Factor Pathway Inhibitor Modulates Thrombus Formation in an In Vivo Model of Rabbit Carotid Artery Stenosis and Endothelial Injury. <i>Circulation</i> , 2000, 102, 113-117.	1.6	46
128	Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine. <i>Biochemical Pharmacology</i> , 1999, 58, 1341-1348.	2.0	24
129	A Simple Method for the Isolation, Cultivation, and Characterization of Endothelial Cells from Rabbit Coronary Circulation. <i>Thrombosis Research</i> , 1999, 96, 329-333.	0.8	11
130	Antithrombotic Effects of Recombinant Human, Active Site-Blocked Factor VIIa in a Rabbit Model of Recurrent Arterial Thrombosis. <i>Circulation Research</i> , 1998, 82, 39-46.	2.0	82
131	Ceruloplasmin impairs endothelium-dependent relaxation of rabbit aorta. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1997, 273, H2843-H2849.	1.5	17
132	Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. <i>American Journal of Cardiology</i> , 1996, 77, 498-502.	0.7	62
133	Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. <i>Nature Medicine</i> , 1996, 2, 35-40.	15.2	171
134	Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis. <i>Circulation</i> , 1996, 93, 1913-1918.	1.6	59
135	Endogenous and Exogenous Nitric Oxide Protect Against Intracoronary Thrombosis and Reocclusion After Thrombolysis. <i>Circulation</i> , 1995, 92, 1005-1010.	1.6	40
136	Local Effect of Serotonin Released during Coronary Angioplasty. <i>New England Journal of Medicine</i> , 1994, 330, 523-528.	13.9	131
137	The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. <i>American Heart Journal</i> , 1993, 125, 11-23.	1.2	48
138	Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: Studies in a rabbit model of coronary artery occlusion-reperfusion. <i>Journal of the American College of Cardiology</i> , 1993, 21, 493-501.	1.2	24
139	Serotonergic Mechanisms in the Regulation of the Human Coronary Circulation in Vivo. <i>Endothelium: Journal of Endothelial Cell Research</i> , 1993, 1, 131-136.	1.7	1
140	Cyclic flow alterations and neointimal proliferation following experimental coronary stenosis and endothelial injury. <i>Developments in Cardiovascular Medicine</i> , 1993, , 385-393.	0.1	0
141	Experimental Carotid Stenosis and Endothelial Injury in the Rabbit: An In Vivo Model to Study Intravascular Platelet Aggregation. <i>Thrombosis and Haemostasis</i> , 1992, 67, 302-305.	1.8	44
142	Specific Platelet Mediators and the Abrupt Progression of Coronary Artery Stenoses. , 1992, , 283-294.		0
143	Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. <i>Journal of the American College of Cardiology</i> , 1991, 17, 101-110.	1.2	44
144	Role of new antiplatelet agents as adjunctive therapies in thrombolysis. <i>American Journal of Cardiology</i> , 1991, 67, 12-18.	0.7	39

#	ARTICLE	IF	CITATIONS
145	Digoxin-induced vasoconstriction of normal and atherosclerotic epicardial coronary arteries. <i>American Journal of Cardiology</i> , 1991, 68, 1274-1278.	0.7	14
146	Divergent Effects of Serotonin on Coronary-Artery Dimensions and Blood Flow in Patients with Coronary Atherosclerosis and Control Patients. <i>New England Journal of Medicine</i> , 1991, 324, 641-648.	13.9	677
147	Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes. <i>American Journal of Cardiology</i> , 1990, 66, G48-G53.	0.7	12
148	Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1990, 66, 1281-1286.	0.7	14
149	Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion. <i>American Heart Journal</i> , 1990, 120, 801-807.	1.2	13
150	Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations. <i>Journal of the American College of Cardiology</i> , 1990, 16, 705-713.	1.2	40
151	Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: Further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo. <i>Journal of the American College of Cardiology</i> , 1990, 15, 718-726.	1.2	41
152	Differential enhancement of postischemic segmental systolic thickening by diltiazem. <i>Journal of the American College of Cardiology</i> , 1990, 15, 737-747.	1.2	51
153	Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries. <i>Journal of the American College of Cardiology</i> , 1989, 13, 755-763.	1.2	320
154	Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion-reperfusion. <i>American Heart Journal</i> , 1988, 115, 499-504.	1.2	46